Atlantic Health System is treating patients in a new Phase II clinical trial of CAR T-cell therapy at Morristown Medical Center.
“A type of immunotherapy for lymphoma known as CAR T-cell therapy has generated a great deal of excitement within the medical community because it uses a patient’s own immune cells to attack their cancer,” said Dr. Mohamad Cherry, medical director of hematology for Atlantic Health System Cancer Care. “Two types of CAR T therapy are FDA-approved for certain types of advanced or recurrent lymphoma. Other CAR T-cell therapies for non-Hodgkin’s lymphoma, including the one we’re testing, are now in clinical trials.”
“We’re excited to achieve this milestone and so far, patients with aggressive B cell lymphomas receiving approved CAR T therapies respond to the treatment almost 80% of the time,” said Dr. Cherry of the therapy, conducted on an outpatient basis and sponsored by Juno Therapeutics.
“We’ve made great progress in treating non-Hodgkin’s lymphoma over the last several years and survival rates have increased,” Dr. Cherry said. “A number of other promising therapies and treatment approaches are now also in clinical trials, including targeted therapy, chemotherapy, radiation therapy, stem cell transplantation, immunotherapy and, very rarely, surgery.”
“While newer types of therapy have revolutionized cancer treatment, most non-Hodgkin’s lymphoma patients receive chemotherapy, often as a combination of chemo drugs or in combination with immunotherapy, targeted therapy or radiation therapy,” said Dr. Cherry. “Some of these combinations are now being further studied in clinical trials to determine the most effective combinations and doses, with the fewest side effects.”
To learn more about study criteria, please go to: atlantichealth.org/research.